Immunogenicity and pharmacokinetics of short, proline-rich antimicrobial peptides

Future Medicinal Chemistry

Volumn 7, Issue 12, 2015, Pages 1581-1596

  Holfeld, Luzia ^a   Herth, Nicole ^a   Singer, David ^a   Hoffmann, Ralf ^a   Knappe, Daniel ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2B; KEYHOLE LIMPET HEMOCYANIN; POLYPEPTIDE ANTIBIOTIC AGENT; PROLINE RICH ANTIMICROBIAL PEPTIDE; PROLINE RICH PROTEIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PROLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EXPERIMENTAL INFECTION; FEMALE; HYBRIDOMA CELL LINE; IMMUNE RESPONSE; IMMUNOGENICITY; LOW DRUG DOSE; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; REPEATED DRUG DOSE; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; HYBRIDOMA; IMMUNOLOGY;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIMICROBIAL CATIONIC PEPTIDES; EPITOPES; FEMALE; HYBRIDOMAS; IMMUNOGLOBULIN G; MICE, INBRED BALB C; PROLINE;

EID: 84940943721     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.91     Document Type: Article

References (53)

1. Hancock REW. Peptide antibiotics. Lancet 349(9049), 418-422 (1997).
2. Boman HG. Antibacterial peptides: basic facts and emerging concepts. J. Intern. Med. 254(3), 197-215 (2003).
3. Barrell PJ, Liew OW, Conner AJ. Expressing an antibacterial protein in bacteria for raising antibodies. Protein Expression Purif. 33(1), 153-159 (2004).
4. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 3(3), 238-250 (2005).
5. Otvos L. The short proline-rich antibacterial peptide family. Cell. Mol. Life Sci. 59(7), 1138-1150 (2002).
6. Krizsan A, Volke D, Weinert S, Strater N, Knappe D, Hoffmann R. Insect-derived proline-rich antimicrobial peptides kill bacteria by inhibiting bacterial protein translation at the 70S ribosome. Angew. Chem. Int. Ed. Engl. 53(45), 12236-12239 (2014).
7. Warrington R, Silviu-Dan F. Drug allergy. Allergy, Asthma, Clin. Immunol. 7(Suppl. 1), S1-S10 (2011).
8. Brinch KS, Frimodt-Moller N, Hoiby N, Kristensen HH. Influence of antidrug antibodies on plectasin efficacy and pharmacokinetics. Antimicrob. Agents Chemother. 53(11), 4794-4800 (2009).
9. Bhunia AK, Johnson MC, Ray B, Belden EL. Antigenic property of pediocin ach produced by Pediococcus-acidilactici H. J. Appl. Bacteriol. 69(2), 211-215 (1990).
10. Bhunia AK. Monoclonal antibody-based enzymeimmunoassay for pediocins of Pediococcus-acidilactici. Appl. Environ. Microbiol. 60(8), 2692-2696 (1994).
11. Levin AS, Barone AA, Penco J et al. Intravenous colistin as therapy for nosocomial infections caused by multidrugresistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin. Infect. Dis. 28(5), 1008-1011 (1999).
12. Butler T, Smith E, Hammarstrom L, Moller G. Polymyxins as inhibitors of polyclonal B-cell activators in murine lymphocyte-cultures. Infect. Immun. 16(2), 449-455 (1977).
13. Wolf AI, Mozdzanowska K, Williams KL et al. Vaccination with M2e-based multiple antigenic peptides: characterization of the B cell response and protection efficacy in inbred and outbred mice. Plos ONE 6(12), e28445 (2011).
14. Richter M, Hoffmann R, Singer D. T-cell epitope-dependent immune response in inbred (C57BL/6J, SJL/J, and C3H/HeN) and transgenic P301S and Tg2576 mice. J. Pept. Sci. 19(7), 441-451 (2013).
15. McManus AM, Otvos L, Hoffmann R, Craik DJ. Conformational studies by NMR of the antimicrobial peptide, drosocin, and its non-glycosylated derivative: effects of glycosylation on solution conformation. Biochemistry 38(2), 705-714 (1999).
16. Casteels P, Ampe C, Jacobs F, Vaeck M, Tempst P. Apidaecins-antibacterial peptides from honeybees. EMBO J. 8(8), 2387-2391 (1989).
17. Bulet P, Dimarcq JL, Hetru C et al. A Novel inducible antibacterial peptide of drosophila carries an O-glycosylated substitution. J. Biol. Chem. 268(20), 14893-14897 (1993).
18. Cociancich S, Dupont A, Hegy G et al. Novel inducible antibacterial peptides from a hemipteran insect, the sapsucking bug Pyrrhocoris apterus. Biochem. J. 300, 567-575 (1994).
19. Otvos L. Antibacterial peptides isolated from insects. J. Pept. Sci. 6(10), 497-511 (2000).
20. Schneider M, Dorn A. Differential infectivity of two pseudomonas species and the immune response in the milkweed bug, oncopeltus fasciatus (Insecta : Hemiptera). J. Invertebr. Pathol. 78(3), 135-140 (2001).
21. Knappe D, Fritsche S, Alber G, Kohler G, Hoffmann R, Muller U. Oncocin derivative Onc72 is highly active against Escherichia coli in a systemic septicaemia infection mouse model. J. Antimicrob. Chemother. 67(10), 2445-2451 (2012).
22. Czihal P, Knappe D, Fritsche S et al. Api88 is a novel antibacterial designer peptide to treat systemic infections with multidrug-resistant gram-negative pathogens. ACS Chem. Biol. 7(7), 1281-1291 (2012).
23. Ostorhazi E, Nemes-Nikodem E, Knappe D, Hoffmann R. In vivo activity of optimized apidaecin and oncocin peptides against a multiresistant, KPC-producing Klebsiella pneumoniae strain. Protein Pept. Lett. 21(4), 368-373 (2014).
24. Knappe D, Piantavigna S, Hansen A et al. Oncocin (VDKPPYLPRPRPPRRIYNR-NH2): a novel antibacterial peptide optimized against gram-negative human pathogens. J. Med. Chem. 53(14), 5240-5247 (2010).
25. Knappe D, Kabankov N, Hoffmann R. Bactericidal oncocin derivatives with superior serum stabilities. Int. J. Antimicrob. Agents 37(2), 166-170 (2011).
26. Knappe D, Zahn M, Sauer U, Schiffer G, Strater N, Hoffmann R. Rational design of oncocin derivatives with superior protease stabilities and antibacterial activities based on the high-resolution structure of the oncocin-dnak complex. Chembiochem 12(6), 874-876 (2011).
27. Otvos L, Wade JD, Lin F, Condie BA, Hanrieder J, Hoffmann R. Designer antibacterial peptides kill fluoroquinolone-resistant clinical isolates. J. Med. Chem. 48(16), 5349-5359 (2005).
28. Otvos et al. combined structural features of PrAMPs from different insect species in one potent antimicrobial designer peptide.
29. Rozgonyi F, Szabo D, Kocsis B et al. The antibacterial effect of a proline-rich antibacterial peptide A3-APO. Curr. Med. Chem. 16(30), 3996-4002 (2009).
30. Singer D, Lehmann J, Hanisch K, Hartig W, Hoffmann R. Neighbored phosphorylation sites as PHF-tau specific markers in Alzheimer's disease. Biochem. Biophys. Res. Commun. 346(3), 819-828 (2006).
31. Pontecorvo G. Polyethylene-glycol (Peg) in production of mammalian somatic-cell hybrids. Cytogenet. Cell Genet. 16(1-5), 399-400 (1976).
32. Davis JM, Pennington JE, Kubler AM, Conscience JF. A simple, single-step technique for selecting and cloning hybridomas for the production of monoclonal-antibodies. J. Immunol. Methods 50(2), 161-171 (1982).
33. Empfehlung zur Blutentnahme bei Versuchstieren, insbesondere kleinen Versuchstieren. GV-Solas. www.gv-solas.de/fileadmin/user-upload/pdf-publikation/ tie-blutentnahme09.pdf
34. Ostorhazi E, Rozgonyi F, Sztodola A et al. Preclinical advantages of intramuscularly administered peptide A3-APO over existing therapies in Acinetobacter baumannii wound infections. J. Antimicrob. Chemother. 65(11), 2416-2422 (2010).
35. Benincasa M, Pelillo C, Zorzet S et al. The proline-rich peptide Bac7(1-35) reduces mortality from Salmonella typhimurium in a mouse model of infection. BMC Microbiol. 10(178), 178-(2010).
36. Zahn M, Berthold N, Kieslich B, Knappe D, Hoffmann R, Strater N. Structural studies on the forward and reverse binding modes of peptides to the chaperone DnaK. J. Mol. Biol. 425(14), 2463-2479 (2013).
37. Liebscher M, Roujeinikova A. Allosteric coupling between the lid and interdomain linker in DnaK revealed by inhibitor binding studies. J. Bacteriol. 191(5), 1456-1462 (2009).
38. Mardirossian M, Grzela R, Giglione C et al. The host antimicrobial peptide Bac7(1-35) binds to bacterial ribosomal proteins and inhibits protein synthesis. Chem. Biol. 21(12), 1639-1647 (2014).
39. Radek K, Gallo R. Antimicrobial peptides: natural effectors of the innate immune system. Semin. Immunopathol. 29(1), 27-43 (2007).
40. Fritsche S, Knappe D, Berthold N, von Buttlar H, Hoffmann R, Alber G. Absence of in vitro innate immunomodulation by insect-derived short proline-rich antimicrobial peptides points to direct antibacterial action in vivo. J. Pept. Sci. 18(10), 599-608 (2012).
41. Tavano R, Segat D, Gobbo M, Papini E. The honeybee antimicrobial peptide apidaecin differentially immunomodulates human macrophages, monocytes and dendritic cells. J. Innate Immun. 3(6), 614-622 (2011).
42. Keitel U, Schilling E, Knappe D et al. Effect of antimicrobial peptides from Apis mellifera hemolymph and its optimized version Api88 on biological activities of human monocytes and mast cells. Innate Immun. 19(4), 355-367 (2013).
43. Zhang GL, Ross CR, Dritz SS, Nietfeld JC, Blecha F. Salmonella infection increases porcine antibacterial peptide concentrations in serum. Clin. Diagn. Lab. Immunol. 4(6), 774-777 (1997).
44. Corrales J, Gordon WL, Noga EJ. Development of an ELISA for quantification of the antimicrobial peptide piscidin 4 and its application to assess stress in fish. Fish Shellfish Immunol. 27(2), 154-163 (2009).
45. Hycult Biotech. www.hycultbiotech.com
46. Cusabio Life Sciences. www.cusabio.com
47. Knappe D, Adermann K, Hoffmann R. Oncocin Onc72 is efficacious against antibiotic-susceptible Klebsiella pneumoniae ATCC 43816 in a murine thigh infection model. Pept. Sci. doi: 10.1002/bip.22668 (2015) (Epub aheadof print).
48. Ostorhazi E, Holub MC, Rozgonyi F et al. Broad-spectrum antimicrobial efficacy of peptide A3-APO in mouse models of multidrug-resistant wound and lung infections cannot be explained by in vitro activity against the pathogens involved. Int. J. Antimicrob. Agents 37(5), 480-484 (2011).
49. Carone FA, Peterson DR. Hydrolysis and transport of small peptides by the proximal tubule. Am. J. Physiol. 238(3), F151-F158 (1980).
50. Diao L, Meibohm B. Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides. Clin. Pharmacokinet. 52(10), 855-868 (2013).
51. Van Dorpe S, Bronselaer A, Nielandt J et al. Brainpeps: the blood-brain barrier peptide database. Brain Struct. Funct. 217(3), 687-718 (2012).
52. Stalmans S, Wynendaele E, Bracke N et al. Blood-brain barrier transport of short proline-rich antimicrobial peptides. Protein Pept. Lett. 21(4), 399-406 (2014).
53. Noto PB, Abbadessa G, Cassone M et al. Alternative stabilities of a proline-rich antibacterial peptide in vitro and in vivo. Protein Sci. 17(7), 1249-1255 (2008).